Stock Ratings / Health Care / DMRA / forecast

OMER (46) KRSA (33) KARD (61) NKTR (33) ⌘ Pro Terminal →

Damora Therapeutics Inc. (DMRA) 12-Month Stock Forecast & Price Target Cone

$22.01 +1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Damora Therapeutics Inc. (DMRA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DMRA)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your DMRA Position Size: $10,000

Shares at $22.01: 454.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $16.32

$7,415

$-2,585 (-25.9%)

12M Consensus BaseTarget $20.92

$9,505

$-495 (-5.0%)

12M Bull Case BreakoutTarget $40.25

$18,287

+$8,287 (+82.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$22	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$38	69%	B
JP MorganUS Large-Cap Research	SELL	$19	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DMRA)

✓Walkthrough of DMRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DMRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.22%📐 HORIZONTAL RANGE

2026-10-30O $21.95H $22.48L $21.05C $22.01VOL 339.5K

RES: $38.09SUP: $17.37SMA50: $23.53SMA200: $25.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DMRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DMRA Butterfly Map → + Track DMRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DMRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DMRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DMRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DMRA)

Health Care Rank #406 of 1016 ⚔️ OMER vs DMRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DMRA vs. OMER, KRSA, KARD, NKTR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Damora Therapeutics Inc. (DMRA) ranks #406 by composite RQD confidence (47/100, grade D) and #319 by equity capitalization ($1.36B). Within this direct 5-issuer industry benchmark cohort, DMRA leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with DMRA at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DMRA ACTIVE Damora Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.85%	$1.36B	Benchmark Subject
OMER Omeros Corporation	D	46/100	—	—	-35.0%	+5.98%	$1.37B	/omer-vs-dmra →
KRSA Korsana Biosciences Inc.	E	33/100	—	—	-5.7%	+0.37%	$1.38B	/krsa-vs-dmra →
KARD Kardigan Inc.	C-	61/100	—	—	—	+4.22%	$1.34B	/kard-vs-dmra →
NKTR Nektar Therapeutics	E	33/100	—	96.0%	-35.0%	+1.63%	$1.34B	/nktr-vs-dmra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001800315

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Damora Therapeutics Inc. (DMRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$209.8M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (+63.9% YoY). On the balance sheet, DMRA closed FY2025 with $260.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$209.8M	-$6.7M	-$6.7M	$260.5M	—
FY2024 (FY)	2024-12-31	$0	-$21.4M	-$18.6M	-$18.6M	$17.1M	—
FY2023 (FY)	2023-12-31	$0	-$38.3M	-$36.9M	-$36.9M	—	—

3. DMRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DMRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Damora Therapeutics Inc. (NASDAQ: DMRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $22.01 (+1.85% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DMRA ranks #406 in composite RQD confidence.

How does DMRA compare to OMER and KRSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMRA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OMER (Omeros Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B) and KRSA (Korsana Biosciences Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -5.7%, cap $1.38B). Among the 5-stock peer group, DMRA leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DMRA?

Per DMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001800315), Damora Therapeutics Inc. generated $0 in revenue, -$209.8M in net income, and -$6.7M in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DMRA trading relative to its 50-day, 200-day, and 52-week technical levels?

DMRA last traded at $22.01 (+1.85% on volume of 460,322 shares), positioning the stock -6.46% below its 50-day simple moving average ($23.53) and -14.22% below its 200-day simple moving average ($25.66). Across its 52-week range of $4.95 to $38.33, DMRA sits at the 51.1% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.26 to $24.76).

DMRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DMRA's 12-month stock price target?

Damora Therapeutics Inc. (DMRA) carries a 12-month consensus base price target of $20.92 (-5% from $22.01), with a bull-case target of $40.25 and a bear-case floor of $16.32.